PHIO vs. KPRX, ENSC, AIMD, PMCB, TLPH, BCDA, AYTU, PHXM, MBIO, and MYNZ
Should you be buying Phio Pharmaceuticals stock or one of its competitors? The main competitors of Phio Pharmaceuticals include Kiora Pharmaceuticals (KPRX), Ensysce Biosciences (ENSC), Ainos (AIMD), PharmaCyte Biotech (PMCB), Talphera (TLPH), BioCardia (BCDA), Aytu BioPharma (AYTU), PHAXIAM Therapeutics (PHXM), Mustang Bio (MBIO), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical products" industry.
Phio Pharmaceuticals vs.
Kiora Pharmaceuticals (NASDAQ:KPRX) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Kiora Pharmaceuticals has a beta of -0.5, indicating that its share price is 150% less volatile than the S&P 500. Comparatively, Phio Pharmaceuticals has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500.
In the previous week, Kiora Pharmaceuticals and Kiora Pharmaceuticals both had 2 articles in the media. Phio Pharmaceuticals' average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of 1.87 indicating that Phio Pharmaceuticals is being referred to more favorably in the news media.
Phio Pharmaceuticals received 19 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. However, 73.91% of users gave Kiora Pharmaceuticals an outperform vote while only 63.16% of users gave Phio Pharmaceuticals an outperform vote.
77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.9% of Kiora Pharmaceuticals shares are held by company insiders. Comparatively, 0.6% of Phio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Kiora Pharmaceuticals' return on equity of 21.32% beat Phio Pharmaceuticals' return on equity.
Kiora Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 184.09%. Phio Pharmaceuticals has a consensus price target of $36.00, indicating a potential upside of 2,030.18%. Given Phio Pharmaceuticals' higher probable upside, analysts clearly believe Phio Pharmaceuticals is more favorable than Kiora Pharmaceuticals.
Phio Pharmaceuticals has lower revenue, but higher earnings than Kiora Pharmaceuticals.
Summary
Kiora Pharmaceuticals beats Phio Pharmaceuticals on 8 of the 13 factors compared between the two stocks.
Get Phio Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PHIO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Phio Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:PHIO) was last updated on 1/13/2025 by MarketBeat.com Staff
